Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer

VIENNA, Austria, January 30 /PRNewswire/ -- EUCODIS Bioscience, a company developing enzymes for the chemical industry, announced today that Thomas Fischer has joined the company as Chief Financial Officer.

"We are excited about the wealth of experience that Thomas brings to EUCODIS Bioscience," said Rudy Pandjaitan, Ph.D., CEO of EUCODIS Bioscience. "His strong background in the life science industry and his close relations with the investment community will be a tremendous asset and help drive the future financial growth of the Company. Thomas joins EUCODIS Bioscience as the Company is launching its first commercial enzyme and is expanding the scope of its industrial collaborations from its current European focus into the US and Asian markets."

Most recently Mr. Fischer served as Chief Financial Officer of Austrianova, a clinical stage biopharmaceutical company that he co-founded in 2001. In this responsibility he successfully raised more than 30 million Euros in two private financing rounds. Prior to that he held senior positions at Aventis CropScience, Germany, and at Nycomed Pharma East Europe/CIS. Before joining the life science industry, Mr. Fischer spent several years in the European consumer goods and construction industries.

Mr. Fischer holds an M.B.A. from Vienna University of Economics and Business Administration, Austria, where he also received his M.Sc.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops enzymes and biocatalytic processes that enable the chemical, pharmaceutical and other industries to establish critical manufacturing processes and to generate superior products.

Based on its proven proprietary technology and led by an experienced management team, EUCODIS Bioscience provides products and services that help its customers to improve efficiencies and to meet growing environmental requirements.

The Company commercializes its enzyme expertise and its versatile and powerful technology in development projects with industrial partners. Current partners include industry leaders such as GlaxoSmithKline, Henkel, and Lohmann Animal Health.

The Company was founded in 2007, as a demerger of the "white biotech" business unit of Eucodis GmbH, a company founded in 2004. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

    For more information, please visit

    Company contact:

    Rudy Pandjaitan, PhD
    CEO EUCODIS Bioscience
    Brunner Strasse 59
    A-1230 Vienna

    Media Contact:
    Frank Butschbacher
    Investor Relations & Communications

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
3. BD Biosciences to Distribute FCS Express
4. MichBio Will Publish 2009 Michigan Biosciences Directory and Resource Guide
5. Cell Biosciences Introduces Kits for Oncoprotein Analysis
6. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
7. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
8. Sigma-Aldrich and Sangamo BioSciences Announce the Achievement of Key Throughput Milestone in Research Reagents Agreement
9. Alliance Biosciences Announces Trade Mission to Singapore with Speaker Presentation at International Lab Design Seminar
10. Cell Biosciences Delivers Next Generation System to Stanford University
11. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... the year and one of the premier annual events for pharmaceutical manufacturing: 2015 ... 8–11 November 2015, where ISPE hosted the largest number of attendees in more ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:11/12/2015)... golden retriever that stayed healthy despite having the gene ... new lead for treating this muscle-wasting disorder, report scientists ... and Harvard and the University of São Paolo in ... pinpoints a protective gene that boosts muscle regeneration, ... Children,s lab of Lou Kunkel , PhD, is ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:10/29/2015)... Oct. 29, 2015   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce that ... Association (MHTA) as one of only three finalists for ... – Small and Growing" category. The Tekne Awards honor ... shown superior technology innovation and leadership. ...
Breaking Biology News(10 mins):